Specialty drugmaker and IBD 50 stock Jazz Pharmaceuticals reported Q2 earnings in line with estimates and affirmed its guidance late Wednesday, but its revenue came up a bit short of expectations. Jazz (JAZZ) said that its earnings rose 19% over the year-earlier quarter to $2.41 a share, while revenue increased 15% to $333.7 million. Analysts expected $335.9 million in revenue. The EPS number matched their estimate, according to Thomson Reuters.
A varied group of companies including hot health and fitness device maker Fitbit (FIT) and luxury electric carmaker Tesla Motors (TSLA) will report quarterly earnings after the market close Wednesday. Also in the group are top-rated specialty-drug maker Jazz Pharmaceuticals (JAZZ) and burger chain Habit Restaurants (HABT), a newly public company. Tesla Motors The automaker and energy storage battery system developer is among the most closely
Stocks went for a wild ride this past week, with a swath of earnings reports from big names. But the roller coaster of Q2 results isn’t slowing down just yet. Ten top-rated IBD 50 stocks are all geared up to issue their quarterly performances: Allergan (AGN), Regeneron Pharmaceuticals (REGN), Jazz Pharmaceuticals (JAZZ), Monster Beverage (MNST), Gray Television (GTN), Paycom Software (PAYC), Criteo (CRTO), Epam Systems (EPAM), AMC Networks (AMCX),